Sign In to View Organizational & Contract Pricing
Select a Size
About This Item
Empirical Formula (Hill Notation):
C4H6N2S
CAS Number:
Molecular Weight:
114.17
Beilstein:
108646
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24
grade
pharmaceutical primary standard
API family
methimazole
manufacturer/tradename
USP
mp
144-147 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
CN1C=CNC1=S
InChI
1S/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7)
InChI key
PMRYVIKBURPHAH-UHFFFAOYSA-N
Gene Information
human ... TPO(7173)
Looking for similar products? Visit Product Comparison Guide
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Methimazole USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Methimazole Tablets
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 2 - Skin Sens. 1
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
M Clementi et al.
American journal of medical genetics, 83(1), 43-46 (1999-03-17)
We report on a further case of congenital anomalies in a child exposed to methimazole during the first trimester of pregnancy (from first to seventh gestational week), and define a specific malformation pattern related to prenatal methimazole exposure and consisting
P Barbero et al.
American journal of medical genetics. Part A, 129A(1), 83-86 (2004-07-22)
We report three patients with bilateral choanal atresia in children prenatally exposed to methimazole (MMI) in order to define a MMI embryopathy clinical pattern. The combination of choanal atresia and other specific malformations strongly resembles previously reported patients exposed to
Fernando Bolaños et al.
Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion, 54(4), 307-310 (2002-11-06)
Long-term thionamide treatment is considered one of the main resources for Graves' hyperthyroidism. Although a 54.2% remission rate in patients so treated in Mexico was previously reported, most articles have shown a wide variation over time. In the present article
Ashish A Vyas et al.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 16(4), 673-676 (2010-05-05)
To report a case of a patient with Graves disease presenting with agranulocytosis induced by methimazole, with subsequent thyroid storm and successful therapeutic use of plasmapheresis. The clinical features and laboratory findings in a patient with agranulocytosis and thyroid storm
Jeanne M Chattaway et al.
The Annals of pharmacotherapy, 41(6), 1018-1022 (2007-05-17)
To evaluate the evidence supporting the use of propylthiouracil (PTU) versus methimazole for the treatment of Graves' disease during pregnancy. An English-language literature search was conducted using MEDLINE (1966-March 2007). Identified articles were then reviewed for additional sources. Search terms
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service